Vanda Pharmaceuticals (VNDA) Misses Q3 EPS by 2c

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of $0.14, $0.02 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $70.1 million versus the consensus estimate of $75 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• The Buckle (BKE) Tops Q2 EPS by 7c, Beats on Revenue
• Arena Group to rename as Paradium.AI, ticker changing to PAAI